epocrates
AAD 2024: LITE study results suggest home phototherapy effective for psoriasis
Data from the Light Treatment Effectiveness (LITE) study presented at the American Academy of Dermatology Annual Meeting showed that home phototherapy is non-inferior to office phototherapy. Both home and office phototherapy demonstrated excellent effectiveness and safety in real world settings. The study, a collaboration between the National Psoriasis Foundation, the University of Pennsylvania Perelman School of Medicine, and the University of Utah, is the largest study of its kind and supports the use of home phototherapy as a first-line treatment option for psoriasis.
- The LITE study, a large pragmatic randomized study embedded in routine clinical practice, compared the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home vs. office-based narrowband ultraviolet B phototherapy for the treatment of plaque or guttate psoriasis across all skin types.
- The study concluded in December 2023 after enrolling 783 patients with skin types I-VI at 42 dermatology practices across the U. S.
- Approximately 60% of patients who completed on average 2 or more sessions per week over a 12-week period of home or office phototherapy achieved clear or almost clear skin.
- More patients randomized to home phototherapy achieved clear/almost clear skin (32.8% vs. 25.6%) and no to small effect on health-related quality of life (52.4% vs. 33.6%) compared to those randomized to phototherapy in the office after 12 weeks of treatment.
- Similar findings were observed in a priori defined subgroups of people with fair, medium complected, and darkly pigmented skin demonstrating that home phototherapy is an excellent alternative to office phototherapy for patients of all skin types.
Source:
Gelfand, J, et al. The light treatment effectiveness (LITE) study: a pragmatic trial of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis in the United States. Late-breaking research: session 1. Presented at: 2024 American Academy of Dermatology Meeting; March 8-12, 2024; San Diego, CA. https://am2024.aad.org/sessions/16895 [link requires log-in].